Transcriptional silencing, as a result of aberrant promoter hypermethylation, is a common mechanism through which genes in cancer cells become inactive. Functional epigenetic screens using demethylating agents to reexpress transcriptional silenced genes may identify such inactivated genes for needing further evaluation. We aimed to identify genes so far not known to be inactivated by promoter hypermethylation in prostate cancer. DU-145 and LNCaP cells were treated with the DNMT inhibitor zebularine. Expression changes of total RNA from treated and untreated cells were compared using an RNA expression microarray. Genes upregulated more than 2-fold were evaluated by RT-qPCR in 50 cases of paired normal and tumor tissues of prostate cancer patients. SARS was found to be downregulated in prostate cancer in 42/50 cases (84%). In addition, GADD45A and SPRY4 showed a remarkable diminished expression (88% and 74%, resp.). The gold standard for promoter hypermethylation-inactivated genes in prostate cancer (GSTP1) was repressed in 90% of our patient samples. ROC analyses reported statistically significant AUC curves in SARS, GADD45A, and GSTP1 and positive Spearman correlations were found between these genes. SARS was discovered to be a novel gene that is repressed in prostate cancer and could therefore be recommended for its involvement in prostate carcinogenesis.
Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer and the fifth leading cause of cancer death among men worldwide, with 1111,689 new cases and 307,471 (6.6%) deaths projected to occur in 2012 [1] . In 2013, cancers of the prostate, lung and bronchus, and colorectum will account for about 50% of all newly diagnosed cancers in the United States; prostate cancer alone will account for 28% (238,500) of incident cases [2] . In Germany, prostate cancer is already the third most cause of cancer death with more than 68,000 newly diagnosed cases (25.2%) and a mortality rate of approximately 12,500 men (10.7%) in 2012 [1] . Despite extensive scientific efforts and technological progress, the molecular mechanisms of development and progression in particular to lethal PCa are still elusive and need further investigation.
Genetic and epigenetic alterations in prostate tumorigenesis, as in all other cancers, accumulate within a multistep transformation process on the cellular level [3, 4] . Aberrant DNA promoter CpG islands hypermethylation of genes is a well-characterized mechanism for transcriptional silencing of tumour suppressor genes in various cancers [5] . Epigenetic silencing associated with promoter hypermethylation has been well documented also in PCa, including GSTP1, RARB, APC, PYCARD, PTGS2, ABCB1, and RASSF1 genes [6] .
One way to identify epigenetically silenced genes in tumor cells is based on reversal of epigenetic silencing by DNA methyltransferases (DNMT) inhibitors such as 5-aza-2-deoxycytidine and the structurally related compound zebularine [7] . We used moderate concentrations of zebularine to reactivate epigenetically silenced genes by means of demethylating cytosine residues resulting in the "reexpression" of the respective genes [8] . Compared to other more frequently used drugs such as azacytidine and decitabine, zebularine is a highly stable hydrophilic inhibitor of DNA methylation with oral bioavailability and low toxicity even after prolonged 2 Journal of Biomarkers administration [9, 10] . We treated androgen insensitive DU-145 and androgen sensitive LNCaP PCa cell lines with moderate doses of zebularine and identified globally silenced genes by RNA microarray analysis of the transcriptome. Through intuitive selection of upregulated and validated genes, we estimated relative gene expression (RGE) profiles for selected candidate genes in 50 patients using paired samples of adjacent normal and tumour prostate tissue.
In agreement with our working hypothesis of methylationinduced transcriptional inactivation, we focused our attempts on genes that are exclusively downregulated in primary PCa. Eventually, we identified, for the first time, seryl-tRNA synthetase (SARS) to be downregulated in almost all PCa cases analysed. SARS was further characterized to qualify as a possible candidate for future epigenetic study approaches in PCa. ∘ C for 16 hrs. Staining and washing were performed in a Fluidics Station 450 (Affymetrix Inc., Santa Clara, CA, USA). The scanning was carried out on a GeneChip Scanner 3000 G7 system (Affymetrix Inc., Santa Clara, CA, USA). The raw data were normalized according to the log scale robust multiarray analysis (RMA) [11] . Briefly, signal intensities were background adjusted to the perfect match (PM) intensities and quantile normalization approach was performed across all arrays of the experiment. After log2, transformation data were global median polished. In order to control the false discovery rate at < 0.05 for array data, we applied the false discovery rate multiple testing correction, according to Benjamini and Hochberg [12] . All RNA chip data have been deposited in the National Center for Biotechnology Information GEO database under accession number GSE51629 (http://www .ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51629).
Materials and Methods

Computational Analyses.
Differentially expressed genes were identified using Microarray Suit 4.0 software (Affymetrix Inc., Santa Clara, CA, USA). Candidate genes were selected according to their fold change upregulation with a cutoff of 2-fold. In addition, we applied the presence of one or more CpG islands in the promoter region of a particular gene as second criteria. EMBOSS CpGPlot program (http://www.ebi.ac.uk/Tools/seqstats/emboss cpgplot/) was used to determine the presence of CpG islands of the respective genes. Furthermore, serial analysis of gene expression (SAGE, http://cgap.nci.nih.gov/SAGE/) was exploited to check for candidates that show the same or even higher expression in normal tissue when compared to tumor tissue.
Quantitative Real-Time PCR (RT-qPCR). RT-qPCR for selected genes was performed on the LightCycler 480
Instrument (Roche Diagnostics GmbH, Mannheim, Germany) in 96-well white plate format and analyzed using proprietary software (v.1.5.0). RT-qPCR was carried out according to the manufacturer's protocol and the MIQE guidelines (Supplementary File S2). For relative quantification, 1/10 of cDNA was amplified using the "Probe Master kit" and proprietary "UPL probe" PCR format (Roche) in a total reaction volume of 10 L. Primer sequences and appropriate probe sets for target and reference genes were derived from the UPL website (http://www.rocheapplied-science.com/sis/rtpcr/upl/ezhome.html). Amplification primers were synthesized by TIB MOLBIOL (TIB MOL-BIOL, Berlin, Germany); UPL hydrolysis-type probes were purchased from Roche Diagnostics GmbH. PCR was run with a preincubation at 95 ∘ C for 10 minutes, followed by cycling (45x) at 95 ∘ C/10 sec and 59 ∘ C/20 sec (Supplementary File S1). All samples were measured in triplicate; each PCR run includes no-template control and interpolate calibrator. mRNA expression levels were normalized for intraand interassay variation by inclusion of a calibrator and PBGD as the reference gene. PCR efficiency was determined using standard curves and ranged between 90% and 98% (Supplementary File S3). Data were analyzed using GenEx Software v. 4.3.7 (MultiD Analyses AB, Göteborg, Sweden, http://multid.se/).
Data Analyses.
Statistical analyses of gene expression data were performed using the statistical programs GraphPad Prism v.6.01 (GraphPad Software Inc., La Jolla, CA) and SPSS 19.0 (IBM Corporation, Somers, NY). Significant differences between paired normal and tumor tissues were calculated using nonparametric Wilcoxon test. Spearman's rank correlations were used to analyze the relationships between expression levels of deregulated genes, as well as between clinical variables. To determine the discriminative potential of deregulated genes between normal and tumor samples and the diagnostic accuracy, we used receiver operating curves (ROC) calculated by MedCalc Software v.12.0 (MedCalc Software, Mariakerke, Belgium). Sample size calculation ( = 5%; power = 80%) for the comparison of the area under the receiver operating characteristics curve of 0.8 (taking into account this value as appropriate discrimination power) with the null hypothesis value 0.5 was calculated to be 28 in each group. values <0.05 (two-tailed) were considered statistically significant in all cases.
Results and Discussion
Epigenetic screens exploiting the effects of demethylating agents to reactivate transcriptionally silenced genes are suitable tools for the discovery of new biomarkers and putative therapeutic targets [13] .
We performed an RNA microarray screen of zebularinetreated and zebularine-untreated prostate cancer cells lines DU-145 and LNCaP and discovered a total of 3449 genes expressed at least ≥1.5-fold in 3 independent experiments. The number of shared upregulated genes in both cell lines was 85 and 31, respectively (Figure 1) .
A total of 91 genes were at least 2-fold upregulated in the two prostate cancer cell lines. By applying additional selection criteria, like the presence of CpG islands in the promoter region and SAGE database-derived expression data towards an elevated intrinsic expression in normal prostate tissues, the number of candidates was further reduced to 52 (Table 2) . Particular emphasis was added on the efficacy of zebularine action, since this drug is known to be less active when compared to other demethylating agents. Therefore, we measured the "demethylating potential" of zebularine indirectly by measuring the reexpression of IFI6 gene that is regulated by hypermethylation of its promoter [14] . Using RT-qPCR, we measured a 19.4-fold (SD ± 4.6) upregulation of IFI6 after treatment with 100 M zebularine for 9 days.
Next, we aimed to validate our candidates in clinical samples to provide evidence that they are indeed diminished in their expression in prostate carcinoma tissues. For verification of our screening assay, we were looking specifically for sprouty homolog 4 (SPRY4) and growth arrest and DNA-damage-inducible, alpha (GADD45A), since these genes were already revealed by similar epigenetic reactivation screens [15] [16] [17] . Central to our measures of relative gene expression (RGE) in 50 matched tumor and normal prostate tissues, however, was the gene for seryl-tRNA synthetase (SARS), so far not described for its diminished expression in prostate cancer. As a gold standard for subsequent comparisons, we used the frequently suppressed glutathione Stransferase 1 (GSTP1, Figure 2 ) [18] that was downregulated in 45 of our prostate tumor tissues (90%, < 0.0001) with median fold change of −2.54 (Table 3) .
SPRY4 was significantly downregulated in this study in 37 tumor specimens (74%, = 0.0007, Figure 2 ) and most of the samples (31/37; 84%) were inhibited more than 1.5-fold (median = −1.64, Table 3 ). Wang et al. reported that the expression of this inhibitor of the growth factor-induced cell responses was downregulated in approximately half of prostate cancers due to promoter hypermethylation. This regulation of SPRY4 by epigenetic inactivation was further substantiated using 5 Aza-dC treatment of LNCaP cells that restored its expression [16] . These results and the observation that the close relative SPRY2 is also regulated by epigenetic modification add further evidence on the role of members of the SPRY family as putative tumor suppressors in prostate cancer [19] .
Another gene that is repressed by promoter hypermethylation is the cell cycle regulator GADD45A (also known as DDIT1) that causes cell cycle arrest by blocking G2-M transition in response to cellular DNA damage [20] . In agreement with findings by Lodygin et al. [15] , we found that this gene repressed in 44 tumor tissues (88%, < 0.0001) with a majority of samples downregulated more than 1.5-fold (median = −2.32, Table 3 and Figure 2 ). The role of GADD45A as an epigenetically regulated and putative therapeutic target is also emphasized by the observation that DNMT inhibitors enhance sensitivity to docetaxel in DU-145 and LNCaP cell lines [21] . Surprisingly, expression of seryl-tRNA synthetase (SARS, SERS, or SERRS) was significantly repressed in the majority of our prostate cancer specimens, although we are aware of evidences for aminoacyl-tRNA synthetases in cancer progression [22] . SARS expression was significantly diminished in 42 cases (84%, < 0.0001) when compared to matched normal tissue and more than half of the downregulated samples (23/42; 55%) were repressed more than 1.5-fold (median = −1.44) ( Table 3 and Figure 2 ). With regard to SARSs possible involvement in prostate carcinogenesis, recently, a unique domain at the C-terminus of almost all vertebrate SARSs (named UNE-S) that links SARS to vascular development by its interaction with vascular endothelial growth factor A (VEGFA) was described [23] . VEGFA itself is a key regulator of angiogenesis that activates tyrosine kinase receptors VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1), respectively [24] . Our own group recently aimed to link angiogenesisrelated factors more closely to prostate cancer progression by discovering decreased transcript levels of VEGFR2 and other endothelial factors such as CD34, CD146, and CAV1 in prostate cancer [25] . It is also noteworthy that SARS is Journal of Biomarkers 5 Table 3 . Table 4 .
an essential regulatory component of selenium metabolism, whereby dietary selenium levels themselves are still a controversial issue in prostate cancer chemoprevention [26, 27] . Next, we performed receiver operating characteristic (ROC) curve analyses of SARS RGE data and compared them to SPRY4, GADD45A, and the reference GSTP1 (Table 4) . ROC area-under-curve (AUC) for SARS (0.816), GADD45A (0.841), and GSTP1 (0.884) was almost the same with regard to value and shape (Table 4 and Figure 3 ), The AUC of SPRY4 compared less well to the other genes (AUC = 0.644). In addition, it should be noted that, at a sensitivity cutoff of 90%, SARS showed only moderate specificity (48%).
Spearman correlation of ration of SARS expression data with proven epigenetically regulated GADD45A and GSTP1 resulted in a positive correlation among these genes (Table 5) . However, we did not find any significant correlation of expression data with pathological parameters like tumor stage, grade, and Gleason scores (data not shown). Since methylation events are known to be differentiation-and age-dependent and occur early in carcinogenesis [28] , we specifically tried to correlate SARS expression to the age of our patients. A Spearman correlation coefficient of = −0.1626 ( = 0.2591) does not demonstrate any significant relationships.
Conclusion
An RNA microarray screen for epigenetically silenced genes in two prostate cancer cell lines revealed 52 candidates that were further analyzed in patient samples for their involvement in cancer development. We were able to verify, in the majority of our samples (88 and 74%), a diminished expression of GADD45 and SPRY4 that were known to be inactivated by hypermethylation in prostate cancer. Comparable results were obtained for a hitherto unknown transcript that now might be linked to prostate carcinogenesis, too. The enzyme SARS that interacts with components of VEGF and selenium pathways was found consistently downregulated in more than 80% of tumor tissues. Therefore, we believe that SARS might be a promising putative target for further (epi)genetic studies in prostate cancer.
